Tisotumab ELISA Kit
Size: 96T
Catalogue Number: DB058018-96
Citations, Manuals and MSDS Available upon request.
Stability and Storage: The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
Detection Method: Colorimetric
Sample Type: Plasma, Serum
Assay Type: Quantitative
Sensitivity: 0.156 μg/ml
Range: 0.31-5 μg/mL
Recovery: 80-120%
Background: Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Based on its high expression on many solid tumors (including ovarian, prostate, bladder, esophageal, endometrial and lung) and its rapid internalization, TF is considered a suitable target for antibody-drug conjugates. In pre-clinical trials tisotumab vedotin has shown strong ability to bind to TF and inhibit tumor growth. Genmab and Seattle Genetics are jointly developing tisotumab vedotin. In a Phase IIa study, preliminary data demonstrated a manageable safety profile and encouraging efficacy (ORR 37%) in relapsed, recurrent or metastatic cervical cancer.
Shipping: 2-8 ℃
For Research Use Only.